期刊
RSC ADVANCES
卷 9, 期 34, 页码 19571-19583出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c9ra02985k
关键词
-
资金
- National Natural Science Foundation of China [81673304, 81703360]
- Open Research Project Foundation of Shanghai Key Laboratory of Regulatory Biology [2018LBR03]
- Natural Science Foundation of Shandong Province [ZR2016HB43]
- Young Taishan Scholars Program [tsqn20161037]
- Shandong Talents Team Cultivation Plan of University Preponderant Discipline [10027]
Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of cancers. First-generation inhibitors are mainly pan-HDACis that target multiple isoforms which might lead to serious side effects. At present, the next-generation HDACis are mainly focused on being class- or isoform-selective which can provide improved risk-benefit profiles compared to non-selective inhibitors. Because of the rapid development in next-generation HDACis, it is necessary to have an updated and state-of-the-art overview. Here, we summarize the strategies and achievements of the selective HDACis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据